News

New cancer target draws €259m
Enlarge image

BusinessUK

New cancer target draws €259m

11.12.2012 - British pharma GlaxoSmithKline fosters its transatlantic ties. Texas-based MD Anderson will receive €259m for a cancer immune therapy programme.

GlaxoSmithKline (GSK) secured a promising cancer immune therapy programme by collaborating with University of Texas MD Anderson from Houston (US). The deal, which allots GSK worldwide exclusive rights, was been made public on 7 December. In total, the pharma company could pay more than €259m in upfront and milestone payments, excluding the royalties of possible therapeutic antibody sales.

The programme in question has been established by former MD Anderson professor Yong-Jun Liu who is now working at the Baylor Research Institute in Dallas. Liu found that an activation of the T cell receptor OX40 (CD134) on the surface of dendritic cells improves the chances of an immune attack mediated by these cells: "T cell recognition of a tumour antigen is not enough to activate the T cells against cancer cells, they need a secondary signal to tell them “that antigen you have is a bad thing, you have to attack,'“ Liu said. Hence, he and his team screened for antibodies that could mimic the natural activator OX40L, which enables amplification of Th2 cell differentiation upon binding to its receptor. Right now the candidates have been boiled down to half a dozen. The collaboration with GSK in this late preclinical stage comes as no surprise for Liu: "It is gratifying to see this important step towards translating a basic science discovery into a potential new therapy that can proceed to clinical trial.“

The agreement between academia and economy is the first pact for MD Anderson’s new Institute for Applied Cancer Science (IACS). This institute is one of several projects of the recently launched ‚Moon Shot Program’ that tries to advance discoveries from basic sciences into the clinic. Dubbed as the „nation’s No. 1 hospital for cancer care“, MD Anderson thinks that „the end of cancer is closer than you think.“ Other cancer types included in the Moon Shots Program are breast and ovarian cancers, leukaemia (AML/MDS as well as CLL), lung cancer, melanoma and prostate cancer.

It is not the first time that a company aims to target OX40. The human MAB oxelumab targets not the receptor but its ligand OX40L. After Phase II trails in allergic asthma patients failed, Roche's US subsidiary Genentech terminated the development of oxelumab (huMAb OX40L) with Danish Genmab in Q2/2011.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/new-cancer-drug-target-draws-eur259m.html

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.75%
  • DIAXONHIT (F)0.79 EUR14.49%
  • ACTIVE BIOTECH (S)12.35 SEK10.27%

FLOP

  • ZELTIA (E)3.69 EUR-8.44%
  • SWEDISH ORPHAN BIOVITRUM (S)13.05 USD-6.12%
  • ALMIRALL (E)17.75 EUR-5.84%

TOP

  • DBV TECHNOLOGIES (F)79.24 EUR50.2%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.8%
  • DIAXONHIT (F)0.79 EUR43.6%

FLOP

  • BIOTEST (D)25.52 EUR-63.3%
  • BIOTECH PHARMACON (N)9.45 NOK-46.0%
  • EVOCUTIS (UK)0.17 GBP-22.7%

TOP

  • ADOCIA (F)86.78 EUR577.4%
  • FORMYCON (D)28.40 EUR323.2%
  • DBV TECHNOLOGIES (F)79.24 EUR317.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.10 SEK-70.6%
  • NEOVACS (F)1.02 EUR-68.6%

No liability assumed, Date: 02.08.2015